CBMX Combimatrix Corp. (MM)

CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that Chief Financial Officer Scott Burell will present a company overview at the 2nd annual Disruptive Growth and Healthcare Conference on Wednesday, February 15, 2017, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time). The conference is being held in New York City.

The live audio portion of the presentation and the accompanying slide presentation will be available at http://investor.combimatrix.com/events.cfm and will be archived for 90 days.

About CombiMatrix Corporation

CombiMatrix Corporation provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. Our testing focuses on advanced technologies, including single nucleotide polymorphism (“SNP”) chromosomal microarray analysis (“CMA”), next generation sequencing (“NGS”), fluorescent in situ hybridization (“FISH”) and high resolution karyotyping. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.

Company Contact:		Investor Contact:
Mark McDonough		LHA
President & CEO, CombiMatrix Corporation		Jody Cain
(949) 753-0624		(310) 691-7100
		jcain@lhai.com